February 16th 2024
A study found that the mRNA-1647 vaccine candidate developed by Moderna elicited strong immune responses. The mRNA vaccine is now in phase 3 clinical trials to determine its effectiveness in protecting against CMV.
COVID-19 Vaccination and People with MS: T Cells Boosted, Antibodies Not So Much
September 5th 2022Research shows that patients with multiple sclerosis who have been treated with drugs that target CD20 B cells drugs, such as Ocrevus and Rituxan, tend to have a weak antibody response. But cellular immunity and T cells are activated. The results suggest a need for vaccines that boost T cells.
Read More